MUMBAI, India -
Release Highlights - Melogliptin continues to demonstrate potential to be the best-in-class in achieving glycemic control with low incidence of hypoglycemia and neutral effect on body weight - Global Phase III trials likely to start by end 2009 - IND approved by USFDA - Glenmark takes a step closer towards becoming the first Indian company to have a truly global innovative drug for the world
In the recently completed 12 week Phase IIb clinical trial in 494 patients with type 2 diabetes mellitus (T2DM), ‘Melogliptin’, Glenmark’s investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycemic control in patients with type 2 diabetes mellitus and exhibited excellent safety and tolerability profile. In addition, patients taking Melogliptin experienced low incidence of hypoglycemia and neutral effect on body weight.
In this 12-week, randomized, double-blind, placebo-controlled, parallel group study, Melogliptin significantly reduced HbA1c from baseline as compared to placebo with a mean average reduction of 0.75% in patients receiving 50mg twice daily dose (p<0001) and 0.60 % in patients receiving 100 mg once daily dose (p<.0001).
In a subgroup of patients with higher baseline HbA1c of 8.5%-10%, Melogliptin reduced HbA1c from baseline as compared to placebo with a mean average reduction of 0.88 % and 1.05 % in patients receiving 100mg once daily dose and 50mg twice daily dose respectively, which compares favorably to reported results of other DPP-4’s.
The Phase IIb results for Melogliptin demonstrate potential for offering class leading improvements in glycemic control and metabolic function. Glenmark recently received IND approval from the USFDA to carry out a clinical study in the US. Glenmark continues to be in discussions with various licensing partners to take the molecule forward.
“Global Phase III trials have been planned with Melogliptin and are due to start at the end of 2009 following regulatory approvals. These studies are designed to evaluate the compound both as monotherapy and in combination with other anti-diabetic therapies in patients with type 2 diabetes mellitus”. said Mr. Glenn Saldanha, MD & CEO, Glenmark Pharmaceuticals Limited. He further added “With this phase II study being successful, we take a step closer towards our objective of becoming the first Indian company to have a truly global innovative drug for the world”
For more information, please log on to :
www.glenmarkpharma.com/media/pdf/releases/Glenmarks_novel_molecule_for_Diabetes_Melogliptin_phase_IIItrail.pdf
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. Glenmark is a leading player in drug discovery and is the recipient of the prestigious SCRIP award for the “Best Pharma Company in the World - SME” and the “Best Company in Emerging Markets” for 2008. For more information on GPL, log on to www.glenmarkpharma.com/
Source: Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Limited, Email : media at glenmarkpharma.com, Jason D’Souza, Tel: +91-22-40189919; Medha Satam, +91-22-40189993
Related Press Releases
Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 AuctionAugust 10th, 2009 WELLESLEY HILLS, Massachusetts -
Joseph F. Finn, Jr., C.P.A.
Glenmark Brings to the Notice of the Authorities Irregularities of the Clinical Investigator at its Jamnagar Site in GujaratJuly 22nd, 2009 MUMBAI -
- A Police Complaint has Been Lodged by Hospital Authorities Citing Fraudulent Activity by the Clinical Investigator Dr. A Bhattacharya Working at the GG Hospital and the MP Shah Medical College
- Glenmark Not Only Acts as the Whistle-Blower but Also Discontinues its Clinical Study at the Mentioned Site
After receiving approval from the Drug Controller General of India(DCGI) for a multi-centre Phase IIb clinical study for its lead COPD/asthma molecule, Oglemilast, Glenmark Pharmaceuticals Limited contracted Omnicare Clinical Research(Omnicare), a leading international CRO to conduct this Phase II asthma study on its behalf.
Long-term Investment Secured - Swiss Foundation Supports Innovative Concept for Patients With DiabetesJuly 2nd, 2009 ZÜRICH - Solianis recently signed an investment agreement with a Swiss foundation which invests its assets in Swiss companies. According to the agreement, this foundation will put CHF 5 million, while the previous investors in Solianis are investing another CHF 3 million.
Living Cell Technologies' Diabetes Clinical Trial Authorized by New Zealand GovernmentJune 23rd, 2009 SYDNEY and AUCKLAND, New Zealand -
Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that the New Zealand Minister of Health, the Honourable Tony Ryall, has authorized LCT's New Zealand Phase I/IIa clinical trial of DIABECELL(R) for insulin dependent diabetes. The authorization confirms the conditions announced on 19 June 2009.
MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 DiabetesJune 15th, 2009 ROCKVILLE, Maryland and INDIANAPOLIS - Phase 3 PROTEGE ENCORE Clinical Trial Initiated
MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the PROTEGE trial achieved its targeted patient enrollment.
Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases ManagementMay 27th, 2009 LYONS, France - Poxel SAS is Set up in Lyons - France
Poxel is a research integrated pharmaceutical Company (RIPCO), spun out from Merck Serono a division of Merck KGaA, Germany, following the decision of Merck Serono to no longer invest in diabetes research and development. It aims to advance promising assets for cardio-metabolic diseases (with a primary focus on Type 2 diabetes) from Research to Phase 2 Clinical Proof-of-Concept, before out-licensing these projects to major pharmaceutical companies.
Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) InhibitorMay 12th, 2009 NERVIANO, Italy - The FDA has approved an Investigational New Drug (IND) application by Nerviano Medical Sciences to begin a phase I clinical study with its selective PLK-1 small molecule inhibitor for the treatment of cancer. PLK-1 is a mitotic kinase required for the proliferation of cancer cells.
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory AffairsApril 20th, 2009 SOUTHAMPTON, England - Vantia Therapeutics, a company developing novel small molecule drugs targeting large underserved medical markets, today announces the appointment of Rachel Morten as Head of Regulatory Affairs. Rachel has more than 24 years experience in global regulatory affairs and product development in the pharmaceutical and animal health industries.
Nuevolution Announces Progress in its Collaboration With Merck & Co. Inc.April 1st, 2009 COPENHAGEN - Nuevolution A/S today announced that Merck & Co. Inc. has chosen to proceed to the second phase of the collaboration agreement announced in June 2008 to apply Nuevolution's proprietary Chemetics(R) drug discovery technology to identify novel small molecule leads against several drug targets.
Vantia Therapeutics' Pipeline Continues to MatureMarch 23rd, 2009 SOUTHAMPTON, England - VA106483 Completes Phase IIa Trial and VA111913 Completes Phase I
Dosing
Vantia Therapeutics, a company focusing on first-in-class
therapies for unmet medical needs, announces further clinical trial progress
with its two lead development compounds, VA106483 for nocturia associated
with benign prostatic hypertrophy (BPH) and VA111913 for dysmenorrhoea. The
Phase IIa trial of VA106483 has completed, while dosing is complete in the
Phase I trial of VA111913.
Related News
Bowl-shaped molecule can capture CO2 from thin airJuly 16th, 2009 WASHINGTON - In a new study, a scientist has said that the accidental discovery of a bowl-shaped molecule that pulls carbon dioxide (CO2) out of the air suggests exciting new possibilities for dealing with global warming, including genetically engineering microbes to manufacture those CO2 "catchers". According to J.
Indian clinical research company to set-up unit in Kuala LumpurJuly 27th, 2009 NEW DELHI - The Ahmedabad-based Veeda Clinical Research organization is entering Malaysia's medical sector by setting up its advanced research unit at the Ampang Hospital in Kuala Lumpur by the year-end. India's fastest-growing clinical research organisation has selected the Ampang Hospital to conduct first phase clinical trials on humans under a quasi-commercial agreement with the Malaysian Health Ministry, The Star Online reports.
Iran announces first trials of postelection protesters to begin SundayJuly 29th, 2009 Report: Iran's first trials of protesters to beginTEHRAN, Iran — The state news agency IRNA says trials of around 20 protesters will begin Sunday, the first trials of those arrested in Iran's postelection turmoil. The announcement Wednesday comes as anger is growing over allegations of abuse against protesters and activists arrested in the fierce crackdown that followed the disputed June 12 presidential election.
Molecule that eats carbon dioxide may fight global warmingJuly 16th, 2009 WASHINGTON - The accidental discovery of a bowl-shaped molecule that pulls carbon dioxide out of the air paves the way for exciting new possibilities to deal with global warming. These possibilities include genetically engineering microbes to manufacture those carbon dioxide "catchers", said J.A.
Contrave - Weight-Loss Drug Trials Meet GoalsJuly 21st, 2009 Contrave is an experimental weight-loss drug developed by Orexigen Therapeutics Inc. It has been shown to significantly aid weight loss
in three late-stage clinical trials according to Associated Press reports.
Life originated on Earth 4 bln yrs ago in form of first self-replicating moleculesMay 14th, 2009 LONDON - In a new research, scientists have developed an experiment demonstrating how life originated on the Earth about 4 billion years ago in the form of the very first self-replicating molecules. According to a report in The Independent, the research was done by John Sutherland and colleagues at Manchester University, UK.
GVK Biosciences forms clinical research alliance with Excel PharmaStudiesApril 14th, 2009 HYDERABAD - GVK Biosciences (GVK BIO), Asia's leading integrated research services provider and Excel PharmaStudies (Excel), a leading Chinese Clinical Research Organization announced a strategic alliance to conduct clinical trials in Asia. The alliance provides clinical trial sponsors access to the scientific skills, talent pool, flexible resourcing, and cost-effectiveness of both India and China.
Iron-binding drug may heal diabetes-related stubborn woundsJuly 28th, 2009 WASHINGTON - A drug used to remove iron from the body has the potential to fight the problem of diabetes-related poor wound healing, according to researchers from Stanford University School of Medicine and the Albert Einstein College of Medicine. Poor wound healing is diabetes' cruellest complications, which could lead to amputation of patients' toes, feet, and even legs.
Scientists edging closer to 'artificial noses'April 24th, 2009 LONDON - Tracking something as elusive as a single molecule has been made possible by minute strings that resonate in characteristic fashion. If a molecule docks onto one of the strings, then it becomes heavier, and its oscillations become measurably slower.
New nanoscale device can measure mass of single moleculeJuly 23rd, 2009 LONDON - For the first time, researchers at California Institute of Technology (Caltech) have used nanoscale devices to develop a technique to determine the mass of a single molecule, in real time. Traditionally, the mass of molecules is measured using mass spectrometry, in which samples consisting of tens of thousands of molecules are ionized, to produce charged versions of the molecules, or ions.
